Argenx stock climbs after ALKIVIA data and analyst upgrades
Published on 08/20/2026 at 07:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Argenx SE (NL0010832176) stock closed at $1,032.86 on August 19, 2026, up $39.87, or 4.02%, and its after-hours quote reached $1,042.25 at 7:49 p.m. ET. The move followed positive Phase 3 ALKIVIA data for Vyvgart Hytrulo, which the company markets in autoimmune myositis.
The same update also helped push the shares to a new one-year high, according to MarketBeat. That matters because the stock has already added 17.4% year to date, while the industry figure cited in the same coverage stood at 5.1%.
ALKIVIA changes the debate
The ALKIVIA readout showed a 15.4-point greater improvement in total improvement score versus placebo, with benefits visible by week 4 and sustained through week 52. In the Zacks report, the effect was also described as consistent across IMNM and dermatomyositis, with a 14.8-point gain in IMNM and a 14.5-point gain in DM.
That is the kind of result that can widen the market view of Vyvgart beyond its existing uses in generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy. It also gives investors a concrete label-expansion angle to weigh against the stock's already elevated valuation.
Targets moved higher
Analyst reaction added another layer. The MarketBeat news feed said Morgan Stanley lifted its target to $1,230, HC Wainwright to $1,202, Wedbush to $1,150, RBC to $1,100 and Truist to $1,095 after the myositis data.
HC Wainwright also raised its fiscal 2027 EPS estimate to $34.82 from $34.38 and its fiscal 2028 EPS estimate to $44.72 from $43.50. Those revisions give the rally a second measurable driver beyond the clinical data itself.
Vyvgart focus
Vyvgart is Argenx's lead therapy and comes in intravenous, subcutaneous and self-injectable formats. The product now sits at the center of the company's expansion strategy, with autoimmune myositis joining a longer list of label opportunities.
Shares hold firm
For investors, the key numbers are straightforward: $1,032.86 at the close, $1,042.25 in extended trading and a 4.02% one-day gain on August 19, 2026. With a $62.12 billion market cap cited in the same news flow and multiple target hikes behind it, the stock is trading with a clear clinical and earnings catalyst in view.
Market snapshot
Company: Argenx SE
ISIN: NL0010832176
Ticker: ARGX
Exchange: NASDAQ
Price as of August 19, 2026, 7:49 p.m. ET: $1,042.25 USD
Market cap: $62.12 billion
Sector / Industry: Healthcare / Biotechnology
Index membership: Nasdaq-100
